179 related articles for article (PubMed ID: 10211151)
1. Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.
Souêtre E; Thwaites RM; Yeardley HL
Br J Psychiatry; 1999 Jan; 174():51-5. PubMed ID: 10211151
[TBL] [Abstract][Full Text] [Related]
2. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
[TBL] [Abstract][Full Text] [Related]
3. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
[TBL] [Abstract][Full Text] [Related]
4. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
[TBL] [Abstract][Full Text] [Related]
5. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
[TBL] [Abstract][Full Text] [Related]
6. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
[TBL] [Abstract][Full Text] [Related]
7. Increase in direct social care costs of Alzheimer's disease in Japan depending on dementia severity.
Takechi H; Kokuryu A; Kuzuya A; Matsunaga S
Geriatr Gerontol Int; 2019 Oct; 19(10):1023-1029. PubMed ID: 31478311
[TBL] [Abstract][Full Text] [Related]
8. Relation between severity of Alzheimer's disease and costs of caring.
Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
[TBL] [Abstract][Full Text] [Related]
9. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
Gustavsson A; Cattelin F; Jönsson L
Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
[TBL] [Abstract][Full Text] [Related]
10. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Lamb HM; Goa KL
Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
[TBL] [Abstract][Full Text] [Related]
12. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
[TBL] [Abstract][Full Text] [Related]
13. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
[TBL] [Abstract][Full Text] [Related]
14. [Cost relation between severity of Alzheimer's disease and cognitive and functional impairment].
López-Pousa S; Garre-Olmo J; Turon-Estrada A; Hernández F; Expósito I; Lozano-Gallego M; Hernández-Ferrándiz M; Gelada-Batlle E; Pericot-Nierga I; Vilalta-Franch J
Med Clin (Barc); 2004 May; 122(20):767-72. PubMed ID: 15207104
[TBL] [Abstract][Full Text] [Related]
15. [Costs of health care resources of ambulatory-care patients diagnosed with Alzheimer's disease in Spain].
Boada M; Peña-Casanova J; Bermejo F; Guillén F; Hart WM; Espinosa C; Rovira J
Med Clin (Barc); 1999 Nov; 113(18):690-5. PubMed ID: 10650570
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
Jones RW; McCrone P; Guilhaume C
Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
[TBL] [Abstract][Full Text] [Related]
17. Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.
Darbà J; Kaskens L; Lacey L
Eur J Health Econ; 2015 Nov; 16(8):895-905. PubMed ID: 25348897
[TBL] [Abstract][Full Text] [Related]
18. The cost of treatment of Alzheimer's disease in The Netherlands: a regression-based simulation model.
McDonnell J; Redekop WK; van der Roer N; Goes E; Ruitenberg A; Busschbach JJ; Breteler MM; Rutten FF
Pharmacoeconomics; 2001; 19(4):379-90. PubMed ID: 11383754
[TBL] [Abstract][Full Text] [Related]
19. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
[TBL] [Abstract][Full Text] [Related]
20. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
Wimo A; Winblad B; Stöffler A; Wirth Y; Möbius HJ
Pharmacoeconomics; 2003; 21(5):327-40. PubMed ID: 12627986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
